Sharissa L. Latham

Sharissa L. Latham is a female medical professional who specializes in treating various conditions such as Triple-Negative Breast Cancer, Breast Cancer, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Primary Amebic Meningoencephalitis, and Thrombocytopenia.

Sharissa L. Latham helps patients by providing specialized care for different types of cancer and other serious illnesses. She uses her knowledge and skills to treat patients with compassion and expertise.

Sharissa L. Latham communicates with patients in a caring and understanding way, which helps them feel comfortable and confident in her care. Patients trust her because she listens to their concerns and explains things clearly.

To stay updated with the latest medical knowledge and research, Sharissa L. Latham regularly attends conferences, reads medical journals, and collaborates with other healthcare professionals. This ensures that she can provide the best possible care to her patients.

Sharissa L. Latham works closely with her colleagues and values teamwork in providing comprehensive care to patients. She believes in sharing knowledge and expertise with other medical professionals to improve patient outcomes.

Through her work, Sharissa L. Latham has positively impacted many patients' lives by providing effective treatments and support during their healthcare journey. Her dedication to patient care and commitment to staying informed on medical advancements have led to improved outcomes for many individuals.

One of Sharissa L. Latham's notable publications is "Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer," published in Nature Communications on March 7, 2024. This research highlights her contribution to advancing knowledge in the field of cancer treatment.

Overall, Sharissa L. Latham is a dedicated and knowledgeable medical professional who goes above and beyond to provide quality care to her patients and contribute to the medical community through her research and collaborations.